Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Sell
25
NBY Quote, Financials, Valuation and Earnings
Last price:
$0.56
Seasonality move
:
0.89%
Day range:
$0.57 - $0.59
52-week range:
$0.36 - $9.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
2.62x
Volume:
32.4K
Avg. volume:
57.4K
1-year change:
-84.32%
Market cap:
$2.8M
Revenue:
$14.7M
EPS (TTM):
-$35.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.29 | -100% | -21.05% | $5.00 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | $0.85 | $2.8M | -- | $0.00 | 0% | 0.06x |
|
ATNM
Actinium Pharmaceuticals
|
$1.52 | $5.00 | $47.4M | -- | $0.00 | 0% | -- |
|
NNVC
Nanoviricides
|
$1.15 | -- | $18M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.20 | $1.00 | $4.3M | -- | $0.00 | 0% | 1.24x |
|
PTN
Palatin Technologies
|
$0.54 | $7.00 | $14M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.18 | $6.00 | $3.3M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.184 | -- | 9.03x |
|
NNVC
Nanoviricides
|
-- | 1.928 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.461 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$12.6M | -95.08% | -95.08% | -12769.14% | -$12M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
NovaBay Pharmaceuticals vs. Competitors
-
Which has Higher Returns NBY or ATNM?
Actinium Pharmaceuticals has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -11511.11%. NovaBay Pharmaceuticals's return on equity of -461.38% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M ATNMActinium Pharmaceuticals-- -$0.37 $36.4M -
What do Analysts Say About NBY or ATNM?
NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 48.6%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 228.95%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals1 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is NBY or ATNM More Risky?
NovaBay Pharmaceuticals has a beta of 0.897, which suggesting that the stock is 10.271% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.274, suggesting its less volatile than the S&P 500 by 127.35%.
-
Which is a Better Dividend Stock NBY or ATNM?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or ATNM?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M ATNMActinium Pharmaceuticals-- -- $81K -$11.6M
-
Which has Higher Returns NBY or NNVC?
Nanoviricides has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About NBY or NNVC?
NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 48.6%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 465.22%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals1 0 0 NNVCNanoviricides0 0 0 -
Is NBY or NNVC More Risky?
NovaBay Pharmaceuticals has a beta of 0.897, which suggesting that the stock is 10.271% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.
-
Which is a Better Dividend Stock NBY or NNVC?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or NNVC?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Nanoviricides's net income of -$2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns NBY or OGEN?
Oragenics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M OGENOragenics-- -$0.27 -- -
What do Analysts Say About NBY or OGEN?
NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 48.6%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 400.25%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals1 0 0 OGENOragenics0 1 0 -
Is NBY or OGEN More Risky?
NovaBay Pharmaceuticals has a beta of 0.897, which suggesting that the stock is 10.271% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.
-
Which is a Better Dividend Stock NBY or OGEN?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or OGEN?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Oragenics's net income of -$3.3M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus 1.24x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M OGENOragenics1.24x -- -- -$3.3M
-
Which has Higher Returns NBY or PTN?
Palatin Technologies has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -2357.27%. NovaBay Pharmaceuticals's return on equity of -461.38% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About NBY or PTN?
NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 48.6%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1200.63%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals1 0 0 PTNPalatin Technologies0 0 0 -
Is NBY or PTN More Risky?
NovaBay Pharmaceuticals has a beta of 0.897, which suggesting that the stock is 10.271% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock NBY or PTN?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or PTN?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Palatin Technologies quarterly revenues of $350K. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Palatin Technologies's net income of -$2.4M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns NBY or TOVX?
Theriva Biologics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About NBY or TOVX?
NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 48.6%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 408.48%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals1 0 0 TOVXTheriva Biologics0 0 0 -
Is NBY or TOVX More Risky?
NovaBay Pharmaceuticals has a beta of 0.897, which suggesting that the stock is 10.271% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock NBY or TOVX?
NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or TOVX?
NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Theriva Biologics's net income of -$4.4M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.06x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
